JOURNAL FOR IMMUNOTHERAPY OF CANCER Journal
Overview
publication venue for
- Correlation of safety and efficacy of atezolizumab therapy across indications. 12. 2024
- Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes. 12. 2024
- Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer. 12. 2024
- Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies. 11. 2023
- FIRST-IN-HUMAN PHASE 1A STUDY OF NG-641, A TUMOUR-SELECTIVE VECTOR EXPRESSING A FAP-TAC BISPECIFIC ANTIBODY AND IMMUNE ENHANCER MODULE, IN PATIENTS WITH METASTATIC/ADVANCED EPITHELIAL TUMOURS (STAR) 2022
- Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. 10. 2022
- A PHASE 1B/2 UMBRELLA STUDY OF ANTI-PD-1 SASANLIMAB IN COMBINATION WITH OTHER THERAPIES FOR PATIENTS WITH STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC): THE LANDSCAPE 1011 TRIAL IN PROGRESS 2021
Identity
Electronic International Standard Serial Number (EISSN)
- 2051-1426
Other
journal abbreviation
- J IMMUNOTHER CANCER